Phase 2, 1 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Cyclophosphamide+Velcade+Dexamethasone (CVd)
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 2, 1 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Cyclophosphamide+Velcade+Dexamethasone (CVd) 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232